Wells Fargo’s Recursion Pharmaceuticals RXRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.1M | Sell |
217,033
-386,695
| -64% | -$1.96M | ﹤0.01% | 3307 |
|
|
2025
Q1 | $3.19M | Buy |
603,728
+145,407
| +32% | +$769K | ﹤0.01% | 2450 |
|
|
2024
Q4 | $3.1M | Buy |
458,321
+343,304
| +298% | +$2.32M | ﹤0.01% | 2495 |
|
|
2024
Q3 | $758K | Buy |
115,017
+37,802
| +49% | +$249K | ﹤0.01% | 3373 |
|
|
2024
Q2 | $579K | Buy |
77,215
+18,698
| +32% | +$140K | ﹤0.01% | 3489 |
|
|
2024
Q1 | $583K | Buy |
58,517
+6,547
| +13% | +$65.3K | ﹤0.01% | 3452 |
|
|
2023
Q4 | $512K | Sell |
51,970
-192,914
| -79% | -$1.9M | ﹤0.01% | 3500 |
|
|
2023
Q3 | $1.87M | Buy |
244,884
+131,612
| +116% | +$1.01M | ﹤0.01% | 2647 |
|
|
2023
Q2 | $846K | Buy |
113,272
+24,644
| +28% | +$184K | ﹤0.01% | 3390 |
|
|
2023
Q1 | $591K | Buy |
88,628
+86,603
| +4,277% | +$578K | ﹤0.01% | 3492 |
|
|
2022
Q4 | $15.6K | Buy |
2,025
+301
| +17% | +$2.32K | ﹤0.01% | 5046 |
|
|
2022
Q3 | $19K | Buy |
1,724
+338
| +24% | +$3.73K | ﹤0.01% | 5106 |
|
|
2022
Q2 | $12K | Sell |
1,386
-8,658
| -86% | -$75K | ﹤0.01% | 5385 |
|
|
2022
Q1 | $71K | Sell |
10,044
-40,601
| -80% | -$287K | ﹤0.01% | 5158 |
|
|
2021
Q4 | $868K | Buy |
50,645
+50,632
| +389,477% | +$868K | ﹤0.01% | 3968 |
|
|
2021
Q3 | $0 | Buy |
+13
| New | – | ﹤0.01% | 7046 |
|